TFA Therapeutics (RAJAF) Common Equity (2020 - 2025)

TFA Therapeutics has reported Common Equity for 6 years, with the latest figure at -$534551.0 in Q4 2025.

• On a quarterly basis, Common Equity fell 42.34% year-over-year to -$534551.0 in Q4 2025; TTM through Dec 2025 was -$534551.0, a 42.34% decrease from a year earlier, with the FY2025 full-year figure at -$534551.0, down 42.34% from the prior year.
• Common Equity was -$534551.0 for Q4 2025 at TFA Therapeutics, down from -$375543.0 in the prior quarter.
• The five-year high for Common Equity was -$151796.0 in Q4 2023, with the low at -$951334.0 in Q4 2022.
• Average Common Equity over 5 years is -$411996.0, with a median of -$325678.0 recorded in 2021.
• The sharpest annual moves came in 2021 and 2023: Common Equity tumbled 2052.77% in 2021, then soared 84.04% in 2023.
• Over 5 years, Common Equity stood at -$275813.0 in 2021, then slumped by 244.92% to -$951334.0 in 2022, then jumped by 84.04% to -$151796.0 in 2023, then sank by 147.4% to -$375543.0 in 2024, then slumped by 42.34% to -$534551.0 in 2025.
• The last three Common Equity figures came in at -$534551.0 (Q4 2025), -$375543.0 (Q4 2024), and -$151796.0 (Q4 2023), per Business Quant data.